Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
8th Apr 20159:57 amRNSDirector Declaration
1st Apr 20159:07 amRNSTotal Voting Rights
23rd Mar 20152:44 pmRNSHolding(s) in Company
12th Mar 20152:53 pmRNSHolding(s) in Company - Replacement
11th Mar 20159:10 amRNSHolding(s) in Company
23rd Feb 20157:00 amRNSVoke® licence - variation granted by MHRA
11th Feb 201511:12 amRNSDirectorate Change
4th Feb 20157:00 amRNSIntegrated Dose Counter Supply Agreement
3rd Feb 201511:37 amRNSHolding(s) in Company
2nd Feb 20159:43 amRNSTotal Voting Rights
29th Jan 20157:00 amRNS£2.2m investment in Atlas Genetics Series C
26th Jan 201512:47 pmRNSDirector/PDMR Shareholding
6th Jan 20153:48 pmRNSDirector/PDMR Shareholding
5th Jan 20152:46 pmRNSTotal Voting Rights
9th Dec 201410:37 amRNSDirector/PDMR Shareholding
4th Dec 20147:00 amRNSHalf Yearly Report
2nd Dec 20141:43 pmRNSBlocklisting Interim Review
28th Nov 201411:31 amBUSForm 8.3 - CSR PLC - Replacement
27th Nov 20142:53 pmBUSForm 8.3 - CSR PLC
27th Nov 20149:00 amRNSHolding(s) in Company
14th Nov 20142:23 pmRNSHolding(s) in Company
12th Nov 201411:09 amRNSAcquisition of Aesica Holdco Limited
12th Nov 201410:06 amRNSTotal Voting Rights
7th Nov 201410:23 amRNSHolding(s) in Company
6th Nov 201412:58 pmRNSHolding(s) in Company
5th Nov 201412:26 pmRNSAdditional Listing
5th Nov 201410:04 amRNSHolding(s) in Company
4th Nov 201412:45 pmRNSTotal Voting Rights
4th Nov 201412:36 pmRNSDirector/PDMR Shareholding
3rd Nov 20149:35 amRNSResults of Rump Placing
3rd Nov 20147:00 amRNSResults of Rights Issue
29th Oct 20144:51 pmRNSDirector/PDMR Shareholding
28th Oct 20145:02 pmRNSHolding(s) in Company
22nd Oct 20147:00 amRNSDevelopment Contract Award
21st Oct 20142:28 pmRNSGerman anti-trust clearance
17th Oct 20148:02 amRNSADMISSION OF NEW ORDINARY SHARES
16th Oct 201412:00 pmRNSResult of EGM
15th Oct 20141:30 pmRNSBlocklisting Interim Review
6th Oct 201410:19 amRNSDirector/PDMR Shareholding
2nd Oct 20141:55 pmRNSHolding(s) in Company
1st Oct 201411:47 amRNSTotal Voting Rights
30th Sep 20143:44 pmRNSPublication of Prospectus
30th Sep 20147:00 amRNSProposed acquisition of Aesica Holdco Limited
12th Sep 20147:00 amRNSMHRA Authorisation of the Voke Inhaler
5th Sep 20143:06 pmRNSHolding(s) in Company
4th Sep 20143:28 pmRNSResult of AGM
4th Sep 20147:00 amRNSInterim Management Statement
29th Jul 20144:28 pmRNSDirector/PDMR Shareholding
29th Jul 201412:10 pmRNSAnnual Financial Report
25th Jul 201410:45 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.